Whalesbook
Pfizer Ltd. has introduced Rimegepant, an Orally Disintegrating Tablet (ODT), in India to treat acute migraines in adults with prior insufficient response to triptans. The medication offers rapid, sustained pain relief for up to 48 hours and can be taken without water. This launch aims to significantly improve migraine management for millions in India by targeting CGRP, a key factor in migraine pain.
Pfizer Ltd. has launched Rimegepant in India, a new medication specifically designed to treat acute migraine in adults who have previously shown an insufficient response to triptan medications. The drug is available in a 75 mg Orally Disintegrating Tablet (ODT) form, which allows for convenient administration without the need for water. Pfizer states that Rimegepant provides rapid and sustained pain relief, lasting for up to 48 hours post-treatment.
The company highlighted that this new medication sets a benchmark for comprehensive migraine care in the Indian market by offering timely and prompt pain relief. Rimegepant works by targeting calcitonin gene-related peptide (CGRP), a crucial element in the pathophysiology of migraines, thereby offering effective relief.
Meenakshi Nevatia, Managing Director of Pfizer Ltd., expressed that this treatment will empower individuals suffering from migraines to manage their pain more effectively and regain productive days sooner than with existing treatment options. The company's note also pointed out the significant burden of migraine in India, affecting approximately 213 million people annually and causing an estimated 17.3 days of lost productivity per year per person.
Impact:
This launch is significant for Pfizer Ltd. in India, potentially boosting its revenue and market share in the pain management segment. It introduces a novel treatment option for a widespread condition, improving patient outcomes and productivity, which could influence healthcare expenditure and pharmaceutical market dynamics.
Rating: 7/10
